An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial

Abstract

Objective

To investigate the effectiveness of curcumin, a natural polyphenolic compound with antioxidant and anti-inflammatory activities, on the frequency of symptoms of anxiety and depression in obese individuals.

Methods

In this double blind, cross-over trial, 30 obese subjects were randomized to receive either curcumin (1 g/day) or placebo for a period of 30 days. Following a wash-out interval of 2 weeks, each subject was crossed over to the alternative regimen for a further 30 days. Severity of anxiety and depression was assessed at baseline and at weeks 4, 6 and 10 of the trial using the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) scales, respectively.

Results

Mean BAI score was found to be significantly reduced following curcumin therapy (P=0.03). However, curcumin supplementation did not exert any significant impact on BDI scores (P=0.7).

Conclusion

Curcumin has a potential anti-anxiety effect in individuals with obesity.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Cassano GB, Pini S, Saettoni M, Dell’Osso L. Multiple anxiety disorder comorbidity in patients with mood spectrum disorders with psychotic features. Am J Psychiatry 1999;156:474–476.

    Article  CAS  PubMed  Google Scholar 

  2. 2.

    Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, et al. Innovative approaches for the development of antidepressant drugs: current and future strategies. J Am Soc Exp Neurother 2005;2:590–611.

    Google Scholar 

  3. 3.

    Skilton MR, Moulin P, Terra J, Bonnet F. Associations between anxiety, depression, and the metabolic syndrome. Biol Psychiatry 2007;62:1251–1257.

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    van Reedt Dortland AK, Vreeburg SA, Giltay EJ, Licht CM, Vogelzangs N, van Veen T, et al. The impact of stress systems and lifestyle on dyslipidemia and obesity in anxiety and depression. Psychoneuroendocrinology 2013;38:209–218.

    Article  PubMed  Google Scholar 

  5. 5.

    Su KP. Inflammation in psychopathology of depression: Clinical, biological, and therapeutic implications. BioMedicine (Netherlands) 2012;2:68–74.

    Google Scholar 

  6. 6.

    Morganti-Kossmann MC, Otto VI, Stahel PF, Kossmann T. The role of inflammation in neurologic disease. Curr Opin Crit Care 2000;6:98–109.

    Article  Google Scholar 

  7. 7.

    Wong ML, Dong C, Maestre-Mesa J, Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry 2008;13:800–812.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. 8.

    Kuppusamy P, Ohnishi ST, Numagami Y, Ohnishi T, Zweier JL. Three-dimensional imaging of nitric oxide production in the rat brain subjected to ischemia-hypoxia. J Cereb Blood Flow Metab 1995;15:899–903.

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008;10:511–545.

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Zheng LD, Tong QS, Wu CH. Growth inhibition and apoptosis inducing mechanisms of curcumin on human ovarian cancer cell line A2780. Chin J Integr Med 2006;12:126–131.

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    Fan CL, Qian Y, Wo XD, Yan J, Gao LP. Effect of curcumin on the gene expression of low density lipoprotein receptors. Chin J Integr Med 2005;11:201–204.

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 2013;39:197–208.

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    Sahebkar A. Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril 2010;94:e75-e76.

    Article  Google Scholar 

  14. 14.

    Sahebkar A, Mohammadi A, Atabati A, Rahiman S, Tavallaie S, Iranshahi M, et al. Curcuminoids modulate prooxidant- antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 2013;27:1883–1888.

    Article  CAS  PubMed  Google Scholar 

  15. 15.

    Panahi Y, Khalili N, Hosseini MS, Abbasinazari M, Sahebkar A. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med 2014;22:851–857.

    Article  PubMed  Google Scholar 

  16. 16.

    Sahebkar A, Chew GT, Watts GF. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res 2014;56:47–66.

    Article  CAS  PubMed  Google Scholar 

  17. 17.

    Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res 2014;28:1461–1467.

    Article  CAS  PubMed  Google Scholar 

  18. 18.

    Panahi Y, Saadat A, Beiraghdar F, Hosseini Nouzari SM, Jalalian HR, Sahebkar A. Antioxidant effects of bioavailability-enhanced curcuminoids in patients with solid tumors: a randomized double-blind placebo-controlled trial. J Funct Foods 2014;6:615–622.

    Article  CAS  Google Scholar 

  19. 19.

    Esatbeyoglu T, Huebbe P, Ernst IMA, Chin D, Wagner AE, Rimbach G. Curcumin-from molecule to biological function. Angew Chem Int Ed Engl 2012;51:5308–5332.

    Article  CAS  PubMed  Google Scholar 

  20. 20.

    Panahi Y, Sahebkar A, Parvin S, Saadat A. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 2012;49:580–588.

    Article  CAS  PubMed  Google Scholar 

  21. 21.

    Panahi Y, Sahebkar A, Amiri M, Davoudi SM, Beiraghdar F, Hoseininejad SL, et al. Improvement of sulphur mustardinduced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br J Nutr 2012;108:1272–1279.

    Article  CAS  PubMed  Google Scholar 

  22. 22.

    Xu Y, Ku B, Tie L, Yao H, Jiang W, Ma X, et al. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res 2006;1122:56–64.

    Article  CAS  PubMed  Google Scholar 

  23. 23.

    Kulkarni SK, Dhir A, Akula KK. Potentials of curcumin as an antidepressant. Sci World J 2009;9:1233–1241.

    Article  CAS  Google Scholar 

  24. 24.

    Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as “curecumin”: from kitchen to clinic. Biochem Pharmacol 2008;75:787–809.

    Article  CAS  PubMed  Google Scholar 

  25. 25.

    Sahebkar A. Are curcuminoids effective C-reactive proteinlowering agents in clinical practice? Evidence from a metaanalysis. Phytother Res 2014;28:633–642.

    Article  CAS  PubMed  Google Scholar 

  26. 26.

    Gilhotra N, Dhingra D. GABAergic and nitriergic modulation by curcumin for its antianxiety-like activity in mice. Brain Res 2010;1352:167–175.

    Article  CAS  PubMed  Google Scholar 

  27. 27.

    Kumar A, Singh A. Possible nitric oxide modulation in protective effect of (Curcuma longa, Zingiberaceae) against sleep deprivation-induced behavioral alterations and oxidative damage in mice. Phytomedicine 2008;15:577–586.

    Article  CAS  PubMed  Google Scholar 

  28. 28.

    Chimakurthy J, Talasila M. Effects of curcumin on pentylenetetrazole-induced anxiety like behaviors and associated changes in cognition and monoamine levels. Psychol Neurosci 2010;3: 239–244.

    Article  CAS  Google Scholar 

  29. 29.

    Available at: http://irct.ir/searchresult.php?keyword=%20j?%20&id=14521&?eld=g&number=1&prt=5&total=10&m=1. Last accessed on December 22, 2014.

  30. 30.

    Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893–897.

    Article  CAS  PubMed  Google Scholar 

  31. 31.

    Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. Aninventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.

    Article  CAS  PubMed  Google Scholar 

  32. 32.

    Lovell MA, Markesbery WR. Oxidative damage in mild cognitive impairment and early Alzheimer’s disease. J Neurosci Res 2007;85:3036–3040.

    Article  CAS  PubMed  Google Scholar 

  33. 33.

    Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956;11:298–300.

    Article  CAS  PubMed  Google Scholar 

  34. 34.

    Hovatta I, Juhila J, Donner J. Oxidative stress in anxiety and comorbid disorders. Neurosci Res 2010;68:261–275.

    Article  CAS  PubMed  Google Scholar 

  35. 35.

    Csiszar A, Wang M, Lakatta EG, Ungvari ZI. Inflammation and endothelial dysfunction during aging: role of NF-?B. J Appl Physiol 2008;105:1333–1341.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. 36.

    Salim S, Chugh G, Asghar M. Inflammation in anxiety. Adv Protein Chem Struct Biol 2012;88:1–25

    Article  CAS  PubMed  Google Scholar 

  37. 37.

    Ruhé HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 2007;12:331–359.

    Article  PubMed  Google Scholar 

  38. 38.

    Kasper MD. The serotonin-1A receptor in anxiety disorders. Biol Psychiatry 2009;66:627–635.

    Article  PubMed  Google Scholar 

  39. 39.

    Goldberg HL, Finnerty RJ. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 1979;136:1184–1187.

    Article  CAS  PubMed  Google Scholar 

  40. 40.

    Azmitia EC, Gannon PJ, Kheck NM, Whitaker-Azmitia PM. Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology 1996;14:35–46.

    Article  CAS  PubMed  Google Scholar 

  41. 41.

    Artigas F, Adell A, Celada P. Pindolol augmentation of antidepressant response. Curr Drug Targets 2006;7:139–147.

    Article  CAS  PubMed  Google Scholar 

  42. 42.

    Xu Y, Ku B, Cui L, Li X, Barish PA, Foster TC, et al. Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brainderived neurotrophic factor expression in chronically stressed rats. Brain Res 2007;1162:9–18.

    Article  CAS  PubMed  Google Scholar 

  43. 43.

    Yu ZF, Kong LD, Chen Y. Antidepressant activity of aqueous extracts of Curcuma longa in mice. J Ethnopharmacol 2002;83:161–165.

    Article  CAS  PubMed  Google Scholar 

  44. 44.

    Nabiuni M, Nazari Z, Abdolhamid Angaji S, Safayi Nejad Z. Neuroprotective effects of curcumin. Aust J Basic Appl Sci 2011;5:2224–2240.

    CAS  Google Scholar 

  45. 45.

    Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, Ghayour-Mobarhan M, et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res 2013;27:374–379.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Majid Ghayour-Mobarhan.

Additional information

Support by the Research Council at the Mashhad University of Medical Sciences, Mashhad, Iran

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Esmaily, H., Sahebkar, A., Iranshahi, M. et al. An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial. Chin. J. Integr. Med. 21, 332–338 (2015). https://doi.org/10.1007/s11655-015-2160-z

Download citation

Keywords

  • Curcuma longa
  • curcumin
  • phenolic
  • psychological disorders
  • Beck Anxiety Inventory scale
  • Beck Depression Inventory scale